To determine the effect of CD13/CD33 expression on real‐world B‐ALL patients, we compared the parameters reflecting clinical courses and outcomes between the CD13/CD33+ and CD13/CD33− groups (Table 1). The gene discussed is ANPEP; the disease is precursor B-cell acute lymphoblastic leukemia.